Cas:182912-74-9 (Pro18,Asp21)-Amyloid β-Protein (17-21) trifluoroacetate salt manufacturer & supplier

Chemical Name:(Pro18,Asp21)-Amyloid β-Protein (17-21) trifluoroacetate salt

CAS.NO:182912-74-9

Synonyms:(Pro18,Asp21)-Amyloid β-Protein (17-21) trifluoroacetate salt

Molecular Formula:C₃₃H₄₃N₅O₈

Molecular Weight:637.72300

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:208.23000

Exact Mass:637.31100

LogP:2.66080

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like (Pro18,Asp21)-Amyloid β-Protein (17-21) trifluoroacetate salt chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(Pro18,Asp21)-Amyloid β-Protein (17-21) trifluoroacetate salt physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(Pro18,Asp21)-Amyloid β-Protein (17-21) trifluoroacetate salt Use and application,(Pro18,Asp21)-Amyloid β-Protein (17-21) trifluoroacetate salt technical grade,usp/ep/jp grade.

Related News: Characteristic APIs are usually more complex in structure, and their synthesis involves a variety of technologies such as chiral synthesis, green synthesis, and catalysis, which requires high research and development capabilities in the production process of API companies. (Pro18,Asp21)-Amyloid β-Protein (17-21) trifluoroacetate salt manufacturer DMF is the main management method for APIs in developed countries in Europe and the United States. Under the DMF system, API companies can submit DMF filing documents to the regulatory authority at any time, but the regulatory authority will not conduct technical reviews on them. When the drug is administered, the regulatory authority will associate and review the drug substance and the preparation. (Pro18,Asp21)-Amyloid β-Protein (17-21) trifluoroacetate salt supplier DMF is the main management method for APIs in developed countries in Europe and the United States. Under the DMF system, API companies can submit DMF filing documents to the regulatory authority at any time, but the regulatory authority will not conduct technical reviews on them. When the drug is administered, the regulatory authority will associate and review the drug substance and the preparation. (Pro18,Asp21)-Amyloid β-Protein (17-21) trifluoroacetate salt vendor With the speeding up of review and approval, the number of approved innovative drugs in China is about to usher in a year of blowout. (Pro18,Asp21)-Amyloid β-Protein (17-21) trifluoroacetate salt factory At present, the additional 300 tons of sunniamine, 300 tons of fluoxamic acid, and 200 tons of cyprodinil have been successfully put into production, and the profitability is good.